Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating an Active Drug in Routine Clinical Practice

Brief summary

A study to assess the real-life management and use of healthcare resources during the initiation of:

- Active drug in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

- Active drug in participants with CLL with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.

Observational study

Chronic Lymphocytic Leukemia
93 patients
Protocol ID:
Observational model:
Time perspective:


Eligibility criteria

Participant attributes:
Male and Female


18 Years and older.

Inclusion Criteria:

- Patient's physician prescribed venetoclax as per product monograph independent of the
patient participation in this study.

- Has chronic lymphocytic leukemia (CLL) and has received at least one prior therapy.

Exclusion Criteria:

- Currently participating in an interventional study.

- Has other condition that, in the opinion of the treating physician, prohibits the
patient from participating in the study or obscures the assessment of the treatment of

All the cities where the clinical studies are located

Calgary - T2N 4Z6
Edmonton - T6G 1Z2
Lethbridge - T1J 1W5
Halifax - B3H 1V7
Brampton - L6R 3J7
Kingston - K7L 2V7
Ottawa - K1H 8L6
Sudbury - P3E 5J1
Thunder Bay - P7B 6V4
Montreal - H3T 1E2
Rimouski - G5L 5T1
Moncton - E1C 6Z8
Winnipeg - R3E 0V9

More information about this study